Phase 2 Trial of GL-0817 With Cyclophosphamide for Squamous Cell Carcinoma of the Oral Cavity

Share this content:
Researchers are evaluating whether GL-0817 is safe and efficacious for preventing recurrence among patients with a head and neck cancer subtype.
Researchers are evaluating whether GL-0817 is safe and efficacious for preventing recurrence among patients with a head and neck cancer subtype.

Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients With High-Risk Squamous Cell Carcinoma of the Oral Cavity1

Principal Investigator: Jeffrey Herpst, RN, OCN, Gliknik Inc

Description: For this multi-center, randomized, phase 2 study (ClinicalTrials.gov Identifier: NCT02873819), researchers are evaluating whether GL-0817, a peptide immunomodulator targeting MAGE-A3, is safe and efficacious for preventing recurrence among patients with squamous cell carcinoma of the oral cavity.

The study has 2 arms: in the first, patients will receive 7 adjuvant injections of GL-0817 with Poly-ICLC and GM-CSF; cyclophosphamide will also be administered prior to the first 3 injections.

In the second arm, patients will receive Poly-ICLC and GM-CSF only, with placebo in place of cyclophosphamide and GL-0817.

The primary outcome is disease-free interval. Secondary outcomes include disease-free survival, overall survival, and adverse events.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/study/NCT02873819.

Status: This study is open and recruiting patients as of June 16, 2017.

This study is sponsored by Gliknik Inc.

Reference

  1. Clinicaltrials.gov. Safety and efficacy study of GL-0817 (with cyclophosphamide) for the prevention of recurrence of squamous cell carcinoma of the oral cavity. NCT02873819. https://clinicaltrials.gov/ct2/show/study/NCT02873819. Accessed June 16, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters